# Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

> **NCT02031419** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 174 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** CC-122
- **DRUG:** CC-223
- **DRUG:** Rituximab
- **DRUG:** CC-122
- **DRUG:** CC-292
- **DRUG:** Rituximab
- **DRUG:** CC-223
- **DRUG:** CC-292
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02031419
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12-18
- **Primary completion:** 2023-12-12
- **Final completion:** 2023-12-12
- **Target enrollment:** 174 (ACTUAL)
- **Why stopped:** Replaced with another clinical trial.
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02031419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02031419, "Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02031419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*